Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Personalized vaccine

A cancer vaccine, hydrophobic technology, applied in the direction of vaccines, multivalent vaccines, biochemical equipment and methods, etc., can solve the problems of lengthy and low efficiency

Pending Publication Date: 2020-04-24
TRANSGENE SA
View PDF48 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, the ability of MVA or other poxviruses to induce robust immune responses against cancer neoantigens has not been tested and remains to be established
In addition, known processes for producing recombinant MVA rely on homologous recombination, which is inefficient and therefore rather lengthy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Personalized vaccine
  • Personalized vaccine
  • Personalized vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0243] Example 1: Immunization with polypeptide constructs

[0244] Vector construction and production

[0245] Such as figure 1 As shown, two MVA constructs MVATG19022 and MVATG19023 were generated to express fusions of 5 peptides derived from multiple antigens separated from each other by a 10 amino acid GS linker for optimal fusion Peptide processing and epitope presentation. Each peptide is a 27mer and contains a validated C57bl / 6 T cell epitope. The pentapeptide coding sequence was placed under the control of the p11k7.5 promoter (SEQ ID NO:8) and this cassette was inserted into deletion III of the MVA genome. More specifically, the pentapeptide fusion comprises FCU1 derived peptide (SEQ ID NO:1), b-Gal derived peptide (SEQ ID NO:2), HPV-16E1 derived peptide (SEQ ID NO: 2) from 5' to 3' 3), HPV-16E7-derived peptide (SEQ ID NO:4) and MUC1-derived peptide (SEQ ID NO:5), wherein there is a 10-mer GS linker before the FCU1 peptide, between the peptides, and after the MUC1...

Embodiment 2

[0264]Example 2: Immunization with CT26 neopeptide constructs

[0265] Selection of new CT26 peptides

[0266] Based on various criteria described in the art, such as low MHC class I binding score, presence of CD8+ T-cell epitopes (Kreiter et al., 2015, Nature 520(7549):692-6) and in the genome of the corresponding CT26 tumor cell line In the presence of single residue mutations, 10 CT26 mutated novel peptides were selected for expression in MVA constructs (amino acid sequences are given in SEQ ID NO: 22-31). Each new peptide is a 27mer containing a mutation at a central position (position 14) and separated from the subsequent new peptide by a 10 amino acid GS linker for optimal processing and epitope presentation.

[0267] Vector construction and generation

[0268] Two MVA constructs were generated, MVTAG19030 and MVTAG19038, respectively, for the expression of the above CT26 neopeptide arranged in two fusions (pentapeptides). The first pentapeptide fusion was placed unde...

Embodiment 3

[0278] Example 3: Human Neopeptide Constructs

[0279] Identification and selection of new peptides

[0280] Whole-exome sequencing (WES) was performed on tumor and germline samples from patients with NSCLC in paired-end format (2x150bp) to identify tumor-specific somatic mutations. Regarding information, raw data is provided by sequencing tools in a standard file format called FASTQ. Each sequencing run generates a FASTQ file that provides short-read sequences and a per base quality score, or Phred score. It is based on the estimated error probability during the base calling step (Cock et al., 2010, Nucl. Acid Res. 38(6):1767-71). In paired-end sequencing, two FASTQ files are generated, one for each end of a library fragment. Therefore, the resulting files must remain paired during the quality filtering step, i.e., the two reads of a pair must have passed the filter. The criteria evaluated in this filtering step are mainly based on Phred scores, especially at the 3' end o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably the entire coding regions of the genome (exome), c) sequencing said target regions (e.g. the exome) from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy, specifically for stimulating T cell immune response.

Description

technical field [0001] The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptides, or a composition comprising such a recombinant poxvirus, and a pharmaceutically acceptable carrier, and said personalized cancer vaccine Use of a vaccine for treating a cancer subject in need thereof. Particular embodiments relate to methods of providing such vaccines or compositions comprising an identification step comprising a) extracting DNA from tumor samples and non-tumor samples, b) selecting target regions, preferably genomic (external exome), c) sequencing the target region (e.g., exome) from the extracted DNA, and d) identifying by comparing DNA sequences obtained from the tumor and non-tumor samples One or more tumor-specific mutations. Embodiments also include methods of treating cancer or preventing its recurrence comprising administering such personalized cancer vaccines. The present invention is of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P35/00C12N7/00
CPCA61K39/0011C12N7/00A61K2039/5254A61K2039/5256A61K2039/627A61K2039/70C12N2710/24043A61P35/00A61K2039/585C12N15/63C12N2710/24134C12Q1/6886C12Q2600/106C12Q2600/156
Inventor K·本贾马N·西尔韦斯特雷J-B·马尔尚B·格雷利耶
Owner TRANSGENE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com